Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

Published:2019-09 Issue:9 Volume:14 Page:1628-1639
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Spigel David R.,McCleod Michael,Jotte Robert M.,Einhorn Lawrence,Horn Leora,Waterhouse David M.,Creelan Ben,Babu Sunil,Leighl Natasha B.,Chandler Jason C.,Couture Felix,Keogh George,Goss Glenwood,Daniel Davey B.,Garon Edward B.,Schwartzberg Lee S.,Sen Rohini,Korytowsky Beata,Li Ang,Aanur Nivedita,Hussein Maen A.

Funder

AbbVie

Aeglea BioTherapeutics

Amgen

Astellas Pharma

AstraZeneca

Bristol-Myers Squibb

Celgene

Celldex

Daiichi-Sankyo

GlaxoSmithKline

Genentech

Roche

Ipsen

Lilly

Merck

Millennium

Novartis

Pfizer

Takeda

Genzyme

Intuitive Surgical

Spectrum Pharmaceuticals

Biogen Idec

Helsinn

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. OPDIVO (nivolumab) [package insert],2017

2. OPDIVO (nivolumab) [summary of product characteristics],2017

3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057);Horn;J Clin Oncol,2017

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials;Cancers;2024-06-14

2. Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute;Cancers;2024-05-26

3. Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study;Cancer Immunology, Immunotherapy;2024-05-11

4. NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice;Experimental Hematology & Oncology;2024-05-09

5. Immune Checkpoint Inhibitors in Geriatric Oncology;Current Oncology Reports;2024-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3